Translating Trial Data to Treatment in Metastatic TNBC
Published: Monday, May 06, 2019
Yuan Yuan, MD, PhD
Immunotherapy, PARP inhibitors, and antibody-drug conjugates (ADCs) have shown efficacy in patients with metastatic triple-negative breast cancer (TNBC), but enhanced genomic understanding and proper patient selection are necessary to determine the optimal use of these agents, explained Yuan Yuan, MD, PhD.
... to read the full story